Search Results - "Turpie, Alexander G"

Efficacy and Safety of the Novel Oral Anticoagulants in Atrial Fibrillation: A Systematic Review and Meta-Analysis of the Literature by DENTALI, Francesco, RIVA, Nicoletta, CROWTHER, Mark, TURPIE, Alexander G. G, LIP, Gregory Y. H, AGENO, Walter

“…Novel oral anticoagulants (NOACs) have been proposed as alternatives to vitamin K antagonists for the prevention of stroke and systemic embolism in patients…”
Get full text

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer by Agnelli, Giancarlo, George, Daniel J, Kakkar, Ajay K, Fisher, William, Lassen, Michael R, Mismetti, Patrick, Mouret, Patrick, Chaudhari, Umesh, Lawson, Francesca, Turpie, Alexander G.G

“…Patients with advanced cancer are at increased risk for venous thrombosis and thromboembolism related to both the effects of cancer and its treatment. In this…”
Get full text

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty by Lassen, Michael R, Ageno, Walter, Borris, Lars C, Lieberman, Jay R, Rosencher, Nadia, Bandel, Tiemo J, Misselwitz, Frank, Turpie, Alexander G.G

“…This trial compared rivaroxaban with enoxaparin for thromboprophylaxis after total knee replacement. Rivaroxaban was superior to enoxaparin in the prevention…”
Get full text

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry by Kakkar, Ajay K, Mueller, Iris, Bassand, Jean-Pierre, Fitzmaurice, David A, Goldhaber, Samuel Z, Goto, Shinya, Haas, Sylvia, Hacke, Werner, Lip, Gregory Y H, Mantovani, Lorenzo G, Turpie, Alexander G G, van Eickels, Martin, Misselwitz, Frank, Rushton-Smith, Sophie, Kayani, Gloria, Wilkinson, Peter, Verheugt, Freek W A

“…Limited data are available on the characteristics, clinical management, and outcomes of patients with atrial fibrillation at risk of stroke, from a worldwide…”
Get full text

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation by Douketis, James D, Spyropoulos, Alex C, Kaatz, Scott, Becker, Richard C, Caprini, Joseph A, Dunn, Andrew S, Garcia, David A, Jacobson, Alan, Jaffer, Amir K, Kong, David F, Schulman, Sam, Turpie, Alexander G.G, Hasselblad, Vic, Ortel, Thomas L

“…In this trial, patients with atrial fibrillation who required warfarin interruption for an elective procedure were assigned to either bridging anticoagulation…”
Get full text

Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor by Turpie, Alexander G G, Kreutz, Reinhold, Llau, Juan, Norrving, Bo, Haas, Sylvia

“…A number of novel oral anticoagulants that directly target factor Xa or thrombin have been developed in recent years. Rivaroxaban and apixaban (direct factor…”
Get more information

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial by Turpie, Alexander GG, MD, Lassen, Michael R, MD, Davidson, Bruce L, MD, Bauer, Kenneth A, MD, Gent, Michael, DSc, Kwong, Louis M, MD, Cushner, Fred D, MD, Lotke, Paul A, MD, Berkowitz, Scott D, MD, Bandel, Tiemo J, MD, Benson, Alice, MS, Misselwitz, Frank, MD, Fisher, William D, MD

“…Summary Background Prophylaxis for venous thromboembolism is recommended for at least 10 days after total knee arthroplasty; oral regimens could enable shorter…”
Get full text

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial by Goldenberg, Neil A, Kittelson, John M, Abshire, Thomas C, Bonaca, Marc, Casella, James F, Dale, Rita A, Halperin, Jonathan L, Hamblin, Frances, Kessler, Craig M, Manco-Johnson, Marilyn J, Sidonio, Robert F, Spyropoulos, Alex C, Steg, P. Gabriel, Turpie, Alexander G. G, Schulman, Sam

“…IMPORTANCE: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. OBJECTIVE: To…”
Get full text

Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study by Ageno, Walter, Dr, Mantovani, Lorenzo G, DSc, Haas, Sylvia, Prof, Kreutz, Reinhold, Prof, Monje, Danja, Dipl Biol, Schneider, Jonas, MD, van Eickels, Martin, MD, Gebel, Martin, PhD, Zell, Elizabeth, MStat, Turpie, Alexander G G, Prof

“…Summary Background The efficacy and safety of the anticoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmonary…”
Get full text

Factors at Admission Associated With Bleeding Risk in Medical Patients Findings From the IMPROVE Investigators by DECOUSUS, Hervé, TAPSON, Victor F, PINI, Mario, PIOVELLA, Franco, SPENCER, Frederick A, SPYROPOULOS, Alex C, TURPIE, Alexander G. G, ZOTZ, Rainer B, FITZGERALD, Gordon, ANDERSON, Frederick A, BERGMANN, Jean-François, CHONG, Beng H, FROEHLICH, James B, KAKKAR, Ajay K, MERLI, Geno J, MONREAL, Manuel, NAKAMURA, Mashio, PAVANELLO, Ricardo

“…Acutely ill, hospitalized medical patients are at risk of VTE. Despite guidelines for VTE prevention, prophylaxis use in these patients is still poor, possibly…”
Get full text

Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases by Turpie, Alexander G.G

“…Anticoagulants are recommended for the prevention and treatment of a wide variety of thromboembolic events. Although existing anticoagulants are effective,…”
Get full text

New oral anticoagulants in atrial fibrillation by Turpie, Alexander G.G.

“…Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet inhibitor) and vitamin K antagonists (VKAs; oral…”
Get full text

International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) by Kakkar, Ajay K., MBBS, PhD, Mueller, Iris, MD, Bassand, Jean-Pierre, MD, Fitzmaurice, David A., MD, Goldhaber, Samuel Z., MD, Goto, Shinya, MD, PhD, Haas, Sylvia, MD, Hacke, Werner, MD, Lip, Gregory Y.H., MD, Mantovani, Lorenzo G., MD, Verheugt, Freek W.A., MD, Jamal, Waheed, MD, Misselwitz, Frank, MD, PhD, Rushton-Smith, Sophie, PhD, Turpie, Alexander G.G., MD

“…Background Atrial fibrillation (AF) is associated with high rates of morbidity and mortality. Patients with AF carry a fivefold increased risk of stroke and…”
Get full text

Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE by Spyropoulos, Alex C., MD, FCCP, Anderson, Frederick A., PhD, FitzGerald, Gordon, PhD, Decousus, Herve, MD, Pini, Mario, MD, Chong, Beng H., MD, PhD, Zotz, Rainer B., MD, Bergmann, Jean-François, MD, Tapson, Victor, MD, FCCP, Froehlich, James B., MD, MPH, Monreal, Manuel, MD, Merli, Geno J., MD, Pavanello, Ricardo, MD, Turpie, Alexander G.G., MD, Nakamura, Mashio, MD, Piovella, Franco, MD, Kakkar, Ajay K., MBBS, PhD, Spencer, Frederick A., MD

“…Background Acutely ill hospitalized medical patients are at risk for VTE. We assessed the incidence of VTE in the observational International Medical…”
Get full text

A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment by Turpie, Alexander G G, Haas, Sylvia, Kreutz, Reinhold, Mantovani, Lorenzo G, Pattanayak, Cassandra W, Holberg, Gerlind, Jamal, Waheed, Schmidt, André, van Eickels, Martin, Lassen, Michael R

“…Rivaroxaban demonstrated superior efficacy and a similar safety profile to enoxaparin for the prevention of venous thromboembolism in the phase III RECORD…”
Get more information

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial by Cohen, Alexander T, Davidson, Bruce L, Gallus, Alexander S, Lassen, Michael R, Prins, Martin H, Tomkowski, Witold, Turpie, Alexander G G, Egberts, Jan F M, Lensing, Anthonie W A

“…Abstract Objective To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous…”
Get full text

Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban — an Oral, Direct Factor Xa Inhibitor — in Patients Undergoing Major Orthopaedic Surgery by Mueck, Wolfgang, Eriksson, Bengt I., Bauer, Kenneth A., Borris, Lars, Dahl, Ola E., Fisher, William D., Gent, Michael, Haas, Sylvia, Huisman, Menno V., Kakkar, Ajay K., Kälebo, Peter, Kwong, Louis M., Misselwitz, Frank, Turpie, Alexander G. G.

“…Background: There is a clinical need for novel oral anticoagulants with predictable pharmacokinetics and pharmacodynamics. Rivaroxaban is an oral direct Factor…”
Get full text

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) by Turpie, Alexander G G, Bauer, Kenneth A, Davidson, Bruce L, Fisher, William D, Gent, Michael, Huo, Michael H, Sinha, Uma, Gretler, Daniel D

“…Betrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of venous thromboembolism (VTE). Its antithrombotic effects had…”
Get more information

Venous and arterial thrombosis--pathogenesis and the rationale for anticoagulation by Turpie, Alexander G G, Esmon, Charles

“…Thromboembolic disorders are major causes of morbidity and mortality. It is well-recognised that the pathogenesis is different for arterial and venous…”
Get more information

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry by Haas, Sylvia, Ten Cate, Hugo, Accetta, Gabriele, Angchaisuksiri, Pantep, Bassand, Jean-Pierre, Camm, A John, Corbalan, Ramon, Darius, Harald, Fitzmaurice, David A, Goldhaber, Samuel Z, Goto, Shinya, Jacobson, Barry, Kayani, Gloria, Mantovani, Lorenzo G, Misselwitz, Frank, Pieper, Karen, Schellong, Sebastian M, Stepinska, Janina, Turpie, Alexander G G, van Eickels, Martin, Kakkar, Ajay K

“…Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of…”
Get full text